Author： Kseneva S. Borodulina E. Semiglazova T. Kulakova N. Tarasova I. Trifonova O. Gridneva T. Udut V.
Publisher： Springer Publishing Company
ISSN： 0007-4888
Source： Bulletin of Experimental Biology and Medicine, Vol.151, Iss.4, 2011-08, pp. : 400-404
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
A 6-month clinical study with active therapeutic intervention was carried out to evaluate the efficacy of moxonidine for the correction of arterial hypertension in 30 patients with metabolic syndrome. Along with the metabolic neutrality for the lipid and purine metabolism, the drug demonstrated a distinct antihypertensive effect, which against the background of pronounced sympatholytic action after 3 months of therapy tends to disappear, which can be prevented by dosage correction. It was shown that the efficacy of moxonidine in reducing insulin resistance in patients with metabolic syndrome directly depends on the severity of hypersympathicotonia manifesting in heart rate over 80 bpm at rest.
Related content
Access to resources
Recommend
By Hermida Ramóón C. Chayáán Luisa Ayala Diana E. Mojóón Artemio Fontao Maríía J. Fernáández Joséé R.
Chronobiology International, Vol. 28, Iss. 6, 2011-07 ,pp. :
By Ayala Diana Hermida Ramon Chayan Luisa Mojon Artemio Fontao Maria Fernandez Jose
Chronobiology International, Vol. 26, Iss. 6, 2009-08 ,pp. :
By Portaluppi Francesco Cortelli Pietro Buonaura Giovanna Calandra Smolensky Michael Fabbian Fabio
Chronobiology International, Vol. 26, Iss. 6, 2009-08 ,pp. :